{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003587","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.831904+00:00","generated_at":"2026-05-24T05:55:49.464804+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025","bullets":["Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.","ACESOT-1051 trial of WEE1 inhibitor APR-1051 enrolling Cohort 5 (70 mg); open-label data expected H2 2025.","ABOYA-119 trial of ATR inhibitor ATRN-119 evaluating BID dosing at Dose Level 7; dose escalation completion H2 2025.","Employment agreement amended for officer John P. Hamill: severance extended to 12 months (18 months post-change-of-control).","R&D expense increased to $9.4M for FY2024 from $7.6M, driven by trial costs and personnel."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003587","json":"https://secwatch.observer/filing/0001558370-25-003587.json","markdown":"https://secwatch.observer/filing/0001558370-25-003587.md","text":"https://secwatch.observer/filing/0001558370-25-003587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/0001558370-25-003587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/apre-20250325x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:55:49.464804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}